Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

  • Revenue in USD (TTM)44.45bn
  • Net income in USD14.65bn
  • Incorporated1994
  • Employees99.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
Kymab Group LtdDeal completed11 Jan 202111 Jan 2021Deal completed7.96%1.45bn
Kiadis Pharma NVAnnounced02 Nov 202002 Nov 2020Announced9.94%254.17m
Principia Biopharma IncDeal completed17 Aug 202017 Aug 2020Deal completed-0.47%3.67bn
Data delayed at least 15 minutes, as of Apr 09 2021 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Zoetis Inc6.68bn1.64bn75.93bn11.30k46.7120.1636.4511.383.423.4213.957.930.53071.356.36590,707.9013.0112.9915.4515.2469.3667.8724.5122.132.309.560.656121.886.636.979.2037.0315.1319.23
Gilead Sciences, Inc.24.69bn123.00m81.98bn13.60k1,143.084.4951.953.320.0570.05719.4914.520.37973.515.831,815,368.000.136911.050.163713.3081.4881.920.360527.471.26--0.632843.079.98-5.43-97.72-63.15-2.7416.09
Sanofi SA (ADR)44.45bn14.65bn127.56bn99.41k8.721.697.842.875.825.8217.7129.960.32891.494.84447,170.3010.554.9812.805.9767.4768.1332.0914.731.3230.480.273155.05-0.69621.40323.6022.79-5.28--
Bristol-Myers Squibb Co42.52bn-9.02bn139.87bn30.25k--3.6892.633.29-4.02-4.0218.7717.030.34233.506.211,405,554.00-7.242.55-8.533.1973.7672.44-21.165.971.47--0.5722192.9562.6220.75-362.14---1.693.99
Amgen, Inc.25.42bn7.26bn143.35bn24.30k20.2215.3013.195.6412.3112.3143.1116.270.41461.655.921,046,255.0011.8411.2014.8013.3675.7780.7028.5733.201.489.080.778144.508.833.25-7.370.91970.46715.16
Eli Lilly And Co24.54bn6.19bn176.92bn35.00k27.1831.2823.537.216.796.7926.915.900.57121.534.71701,137.1014.4210.2820.1814.5477.6677.1925.2419.521.0821.340.740256.069.954.2233.5520.794.538.16
AbbVie Inc45.80bn4.56bn189.79bn47.00k39.6814.5217.114.142.712.7126.917.410.38226.016.43974,553.203.867.734.739.7266.4173.8110.0918.070.72795.370.867997.1537.6914.91-41.90-2.408.4518.50
Data as of Apr 09 2021. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

4.20%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 202040.00m1.59%
Fisher Asset Management LLCas of 31 Dec 202018.21m0.72%
Fidelity Management & Research Co. LLCas of 31 Dec 202012.92m0.51%
BlackRock Investment Management LLCas of 31 Dec 20208.41m0.33%
Managed Account Advisors LLCas of 31 Dec 20205.68m0.23%
Hotchkis & Wiley Capital Management LLCas of 31 Dec 20205.40m0.21%
Invesco Advisers, Inc.as of 31 Dec 20205.13m0.20%
Strategic Advisers LLCas of 31 Dec 20203.94m0.16%
Lazard Asset Management LLCas of 31 Dec 20203.02m0.12%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20203.01m0.12%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.